Published in Antimicrob Agents Chemother on January 01, 1981
Comparative activities of 13 beta-lactam antibiotics. Antimicrob Agents Chemother (1982) 4.13
Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics. Antimicrob Agents Chemother (1982) 1.46
Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods. Antimicrob Agents Chemother (1982) 1.22
Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother (1982) 1.20
Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1981) 0.93
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother (1980) 9.02
In vitro activity of thienamycin. Antimicrob Agents Chemother (1978) 8.76
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob Agents Chemother (1980) 5.47
Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) (1979) 4.82
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1991) 6.17
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Books in clinical practice 1971-1975. A selected and annotated list for medical practitioners, indexed by subject and author. Postgrad Med (1974) 3.42
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
In vitro activity of 5-fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother (1973) 2.54
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun (1971) 2.48
Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol (1969) 2.23
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother (1975) 2.10
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
New method for susceptibility testing with antifungal agents. Antimicrob Agents Chemother (1975) 1.83
In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 1.82
In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia (1985) 1.76
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med (1987) 1.65
Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry (2000) 1.65
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother (1977) 1.61
In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrob Agents Chemother (1977) 1.60
In vitro studies with cefazolin. Antimicrob Agents Chemother (1974) 1.55
In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis (1989) 1.52
In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother (1984) 1.48
Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing. J Infect Dis (1977) 1.47
In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother (1972) 1.38
New medium for in vitro susceptibility studies with amphotericin B. Antimicrob Agents Chemother (1976) 1.37
Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrob Agents Chemother (1978) 1.36
Dematiaceous fungal pathogens isolated from nature. Mycopathologia (1980) 1.33
The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med (1981) 1.31
Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis (1985) 1.22
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Detection of candida antigenemia by counterimmunoelectrophoresis in patients with invasive candidiasis. J Infect Dis (1979) 1.20
In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses (1990) 1.20
Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Microbiol (1982) 1.19
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Therapeutic failures with miconazole. Antimicrob Agents Chemother (1978) 1.14
Laboratory evaluation of serological tests for systemic candidiasis: a cooperative study. J Clin Microbiol (1977) 1.10
Light sensitivity of prepared solutions of amphotericin B. Am Rev Respir Dis (1973) 1.09
In vivo studies with ambruticin in murine histoplasmosis. Antimicrob Agents Chemother (1978) 1.09
Exoantigen test for differentiation of Exophiala jeanselmei and Wangiella dermatitidis isolates from other dematiaceous fungi. J Clin Microbiol (1984) 1.08
Exoantigen test for Cladosporium bantianum, Fonsecaea pedrosoi, and Phialophora verrucosa. J Clin Microbiol (1986) 1.08
In vitro studies with ambruticin, a new antifungal antibiotic. Antimicrob Agents Chemother (1978) 1.07
In vitro susceptibility studies with netilmicin: comparison of a 10-microgram netilmicin disk with a standardized 10-microgram gentamicin disk. Antimicrob Agents Chemother (1978) 1.06
A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia (1982) 1.05
Near-drowning complicated by brain abscess due to Petriellidium boydii. Arch Neurol (1982) 1.05
Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery. JAMA (1980) 1.05
Evaluations of a patient isolator system. I. Evaluations of subsystems and procedures for sterilization and concurrent sanitation. Arch Environ Health (1965) 1.04
Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin. Antimicrob Agents Chemother (1976) 1.01
Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) (1967) 0.99
In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia (1983) 0.99
In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) (1970) 0.97
Brain abscess caused by Cladosporium trichoides. Arch Intern Med (1976) 0.97
Bioassay for miconazole. Antimicrob Agents Chemother (1977) 0.96
In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents. Eur J Clin Microbiol (1983) 0.96
Diffusion disk susceptibility testing with cefaclor. Antimicrob Agents Chemother (1978) 0.95
Isolation of cladosporium trichoides from nature. Mycopathologia (1977) 0.95
In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B. Chemotherapy (1978) 0.93
Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility tests. Antimicrob Agents Chemother (1979) 0.91
Biochemical serogrouping of clinical isolates of Cryptococcus neoformans. Diagn Microbiol Infect Dis (1987) 0.90
Studies on the mode of action of 5-fluorocytosine in Aspergillus species. Chemotherapy (1979) 0.89
Evaluations of a patient isolator system. 3. Microbial contamination of the isolator interior. Arch Environ Health (1965) 0.89
In vitro studies with cephanone. Antimicrob Agents Chemother (1974) 0.89
In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia (1984) 0.88
In vitro and in vivo activity of hamycin against Blastomyces dermatitidis. J Bacteriol (1969) 0.86
Growth of Candida in casein hydrolysate solutions. N Engl J Med (1972) 0.86
Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria. Eur J Clin Microbiol (1983) 0.85
Agar disk diffusion susceptibility tests with cilofungin (LY 121019). J Med Vet Mycol (1991) 0.84
Etiological significance of Pityrosporum orbiculare in tinea versicolor. Sabouraudia (1963) 0.84
Hydrophobic and adherence properties of Clostridium difficile. Eur J Clin Microbiol (1986) 0.82
In vitro activity of five oral cephalosporins against anaerobic pathogenic bacteria. J Infect Dis (1977) 0.82
Cryptococcal pyelonephritis. N Engl J Med (1968) 0.82
In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center study. Am J Clin Pathol (1979) 0.81
In vitro studies with cefotaxime: disk diffusion susceptibility tests. J Clin Microbiol (1982) 0.81
Experimental bacterial peritonitis in mice. J Surg Res (1966) 0.81
Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J Sex Marital Ther (2000) 0.81
Availability of active amphotericin B after filtration through membrane filters. Am Rev Respir Dis (1977) 0.79
A spectral unfolding method to determine source depth distribution. Phys Med Biol (1980) 0.78
Heritability of functioning in families with schizophrenia in relation to neurocognition. Schizophr Res (2012) 0.78
Cryptococcosis in renal transplant patients. Proc Clin Dial Transplant Forum (1977) 0.77
Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels. Mykosen (1986) 0.76
In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia (1984) 0.76
In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy (1984) 0.76
Effect of inoculum size on in vitro susceptibility testing with lincomycin. Appl Microbiol (1968) 0.75
Effects of purines and pyrimidines on the fungistatic activity of 5-fluorocytosine in Aspergillus species. Antimicrob Agents Chemother (1977) 0.75
Gamma-ray imaging with stochastic apertures. Appl Opt (1974) 0.75
Comparative in vitro studies with netilmicin, amikacin, gentamicin, sissomicin and tobramycin. J Antimicrob Chemother (1979) 0.75
The RES-system--a concept of reverse isolation. Mil Med (1966) 0.75
Cryptococcal meningitis in pregnancy. Obstet Gynecol (1983) 0.75
Demonstration of a hemorrhagenic vascular factor in sera from stressed animals. Am J Physiol (1966) 0.75
Fungal infections. Clin Pharmacol Ther (1974) 0.75
The unitized patient isolator: a microbiological demonstration of its reliability. Mil Med (1966) 0.75
Existence of Sporothrix schenckii as a pulmonary saprophyte. Chest (1978) 0.75
In vitro and in vivo studies on synergistic antifungal activity. Contrib Microbiol Immunol (1977) 0.75
Evaluations of a patient isolator system. II. Distribution profiles of patient microflora during prolonged isolator confinement. Arch Environ Health (1965) 0.75
Fungus balls of the urinary tract. South Med J (1979) 0.75
Stability of amphotericin B in polyvinvl chloride intravenous infusion bags. Am Rev Respir Dis (1975) 0.75
In vitro studies with sisomicin and gentamicin. Chemotherapy (1976) 0.75
Synergising tools for capacity assessment and One Health operationalisation. Rev Sci Tech (2019) 0.75